Prospective hospital-based case–control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009–2010 using matched hospital and test-negative controls

BMC Infectious Diseases

Ole Wichmann³  Christian Traeder²  Benedikt Greutélaers⁴  Matthias Nachtnebel⁴  Gerhard Falkenhorst³  Brunhilde Schweiger¹  Pernille Jorgensen³  Wiebke Hellenbrand³ 

[1]National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany

[2]Department of Infectious Diseases, Vivantes Auguste-Viktoria Klinik, Berlin, Germany

[3]Immunization Unit, Department of Infectious Disease Epidemiology, Robert Koch Institute, DGZ-Ring 1, 13086 Berlin, Germany

[4]Post Graduate Training in Applied Epidemiology, Robert Koch Institute, Berlin, Germany

关键词: Risk factors;    Hospitalization;    Case–control study;    Vaccine effectiveness;    H1N1;    Influenza;   

Others  :  1175364
DOI  :  10.1186/1471-2334-12-127

 received in 2011-09-28, accepted in 2012-05-31,  发布年份 2012

【 摘 要 】

Background

We performed a case–control study to estimate vaccine effectiveness (VE) for prevention of hospitalization due to pandemic influenza A(H1N1)pdm09 (pH1N1) and to identify risk factors for pH1N1 and acute respiratory infection (ARI) in 10 hospitals in Berlin from December 2009 to April 2010.

Methods

Cases were patients aged 18–65 years with onset of ARI ≤10 days before admission testing positive for pH1N1 by PCR performed on nasal and throat swabs or by serological testing. Cases were compared to (1) matched hospital controls with acute surgical, traumatological or other diagnoses matched on age, sex and vaccination probability, and (2) ARI patients testing negative for pH1N1. Additionally, ARI cases were compared to matched hospital controls. A standardized interview and chart review elicited demographic and clinical data as well as potential risk factors for pH1N1/ARI. VE was estimated by 1-(Odds ratio) for pH1N1-vaccination ≥10 days before symptom onset using exact logistic regression analysis.

Results

Of 177 ARI cases recruited, 27 tested pH1N1 positive. A monovalent AS03-adjuvanted pH1N1 vaccine was the only pandemic vaccine type identified among cases and controls (vaccination coverage in control group 1 and 2: 15% and 5.9%). The only breakthrough infections were observed in 2 of 3 vaccinated HIV positive pH1N1 patients. After exclusion of HIV positive participants, VE was 96% (95%CI: 26-100%) in the matched multivariate analysis and 46% (95%CI: -376-100%) in the test-negative analysis. Exposure to children in the household was independently associated with hospitalization for pH1N1 and ARI.

Conclusions

Though limited by low vaccination coverage and number of pH1N1 cases, our results suggest a protective effect of the AS03-adjuvanted pH1N1 vaccine for the prevention of pH1N1 hospitalization. The use of hospital but not test-negative controls showed a statistically protective effect of pH1N1-vaccination and permitted the integrated assessment of risk factors for pH1N1-infection. To increase statistical power and to permit stratified analyses (e.g. VE for specific risk groups), the authors suggest pooling of future studies assessing effectiveness of influenza vaccines for prevention of severe disease from different centres.

【 授权许可】

   
2012 Hellenbrand et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

【 参考文献 】

• [1]Chan M: World now at the start of 2009 influenza pandemic. WHO, Geneva; 2009. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html webcite. 2009. 21-9-2009
• [2]Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, et al.: Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009, 361:680-689.
• [3]Poggensee G, Gilsdorf A, Buda S, Eckmanns T, Claus H, Altmann D, Krause G, Haas W, RKI Working Group: The first wave of pandemic influenza (H1N1) 2009 in Germany: from initiation to acceleration. BMC Infect Dis 2010, 10:155. BioMed Central Full Text
• [4]Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM: Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28:1740-1745.
• [5]Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P: AS03A-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010, 51:668-677.
• [6]Gilsdorf A, Poggensee G: Working group pandemic influenza A(H1N1)v: influenza A(H1N1)v in Germany: the first 10,000 cases. Euro Surveill 2009, 14:1-4.
• [7]Walter D, Heiden Mad, Reiter S, Krause G, Wichmann O: Monitoring pandemic influenza A(H1N1) vaccination coverage in Germany 2009/10 - results from thirteen consecutive cross-sectional surveys. Vaccine 2011, 29:4008-4012.
• [8]Gesundheit Senatsverwaltung für, Umwelt Verbraucherschutz und: Ergänzende FAQs zum verwendeten Impfstoff und zum Ablauf der Impfung gegen Influenza A/H1N1 in Berlin (Stand: 16.10.2009) [Additional FAQs regarding the available vaccine and procedures for vaccinating against Influenza A/H1N1 in Berlin (Dated: 16.10.2009)]. Senatsverwaltung für Gesundheit, Verbraucherschutz und Umwelt, Berlin; 2009. http://www.berlin.de/imperia/md/content/sen-gesundheit/notfallvorsorge/pandemie/impfen/erg__nzende_faqs_b__rger.pdf?start&ts=1268747044&file=erg__nzende_faqs_b__rger.pdf webcite
• [9]Demicheli V, Di PC, Jefferson T, Rivetti A, Rivetti D: Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007, (2):CD001269.
• [10]Jefferson T, DiPietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E: Vaccines for preventing influenza in the elderly (Review). Cochrane Database Syst Rev 2010, (7):CD004876.
• [11]Koch-Institut R: Telefonische Erhebung zur Impfung gegen die pandemische Influenza (H1N1) 2009 [Telephone survey regarding vaccination against pandemic influenza (H1N1) 2009]. Epidemiol Bull 2010, 13:114-115.
• [12]Schulze M, Nitsche A, Schweiger B, Biere B: Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCR. PLoS One 2010, 5:e9966.
• [13]Biere B, Bauer B, Schweiger B: Differentiation of influenza B virus lineages yamagata and victoria by real-time PCR. J Clin Microbiol 2010, 48:1425-1427.
• [14]Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM: Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
• [15]Cowling BJ, Chan KH, Fang VJ, Lau LLH, So HC, Fung ROP, Ma ESK, Kwong ASK, Chan CW, Tsui WWS, et al.: Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med 2010, 362:2175-2184.
• [16]De Serres G, Rouleau I, Hamelin M-È, Quach C, Skworonski D, Flamand L, Boulianne N, Li Y, Carbonneau J, Bourgault A-M, et al.: Contagious period for pandemic (H1N1) 2009. Emerg Infect Dis 2010, 16:783-788.
• [17]Suess T, Buchholz U, Dupke S, Grunow R, Matthias an dH, Heider A, Biere B, Schweiger B, Haas W, Krause G, et al.: Shedding and transmission of novel influenza virus A/H1N1 infection in households--Germany, 2009. Am J Epidemiol 2010, 171:1157-1164.
• [18]Lee N, Chan PK, Hui D, Rainer TH, Wong E, Choi K-W, Lui GC, Wong BC, Wong RY, Lam W-Y, et al.: Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009, 200:492-500.
• [19]Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P: Duration of Influenza A shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007, 28:1071-1076.
• [20]Arbeitsgemeinschaft Influenza: Bericht zur Epidemiologie der Influenza in Deutschland Saison 2009/10. Robert Koch-Institute, Berlin; 2011.
• [21]Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez-Vilar S, Silvestre-Silvestre E, Calvo-Mas C, Safont-Adsuara L, Ruiz-García M: Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case–control study. Vaccine 2010, 28:7460-7467.
• [22]Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina MJ, Nguyen-Van-Tam JS, Read RC, Warren FC, et al.: Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101.
• [23]Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Sebastianpillai P, Ellis J, Carman W, Wreghitt T, Watson J, et al.: Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009–2010. Euro Surveill 2011, 16(2):pii=19763. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19763 webcite
• [24]Van Buynder PG, Dhaliwal JK, Van Buynder JL, Couturier C, Minville-Leblanc M, Garceau R, Tremblay FW: Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi Viruses 2010, 4:171-178.
• [25]Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, Rizzo C, Nunes B, Pitigoi D, Larrauri Cámara A, Mosnier A, et al.: Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case–control study. PLoS Med 2011, 8:e1000388.
• [26]Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J: Vaccine effectiveness in pandemic influenza – primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess 2010, 14:313-346.
• [27]Williams C, Schweiger B, Diner G, Gerlach F, Haaman F, Krause G, Nienhaus A, Buchholz U: Seasonal influenza risk in hospital healthcare workers is more strongly associated with household than occupational exposures: results from a prospective cohort study in Berlin, Germany, 2006/07. BMC Infect Dis 2010, 10:8. BioMed Central Full Text
• [28]Emborg H-D, Krause TG, Hviid A, Simonsen J, Molbak K: Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009–10. BMJ 2012, 344:d7901.
• [29]Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, et al.: Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case–control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011, 342:c7297.
• [30]Andrews N, Waight P, Yung CF, Miller E: Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011, 203:32-39.
• [31]Ortqvist A, Berggren I, Insulander M, de Jong B, Svenungsson B: Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza a(H1N1)v in stockholm county, Sweden. Clin Infect Dis 2011, 52:1203-1211.
• [32]Castilla J, Morán J, Martinez-Artola V, Fernández-Alonso M, Guevara M, Cenoz MG, Reina G, Alvarez N, Arriazu M, Elía F, et al.: Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009–2010: cohort and case–control study. Vaccine 2011, 29:5919-5924.
• [33]Bickel M, Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, Von HN, Herrmann E, Doerr HW, Brodt HR, et al.: Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24:F31-F35.
• [34]Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, et al.: Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine 2011, 29:1359-1363.
• [35]Robert Koch-Institut: Repräsentative telefonische Erhebung zur Impfung gegen die pandemische Influenza (H1N1) 2009. Ergebnisse aus Befragungen bis April 2010 [Representative telephone survey on vaccination against pandemic influenza (H1N1) 2009. Results to April 2010]. Epidemiol Bull 2010, 25:237-238.
• [36]Skull SA, Andrews RM, Byrnes GB, Kelly HA, Nolan TM, Brown GV, Campbell DA: Validity of self-reported influenza and pneumococcal vaccination status among a cohort of hospitalized elderly inpatients. Vaccine 2007, 25:4775-4783.
• [37]Grimes DA, Schulz KF: Compared to what? Finding controls for case–control studies. Lancet 2005, 365:1429-1433.
• [38]Wacholder S, McLaughlin JK, Silverman DK, Mandel JS: Selection of controls in case–control studies I.Principles. Am J Epidemiol 1992, 135:1019-1028.
• [39]Wacholder S, Silverman DK, McLaughlin JK, Mandel JS: Selection of Controls in Case–control Studies II. Types of Controls. Am J Epidemiol 1992, 135:1029-1041.
• [40]Valenciano M, Kissling E, Ciancio BC, Moren A: Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine 2010, 28:7381-7388.
• [41]Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, Orenstein WA: Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 2007, 36:623-631.
• [42]Skowronski DM, De SG, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, Rosella LC, Dickinson JA, Gilca R, Sethi P, et al.: Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med 2010, 7:e1000258.
• [43]Janjua NZ, Skowronski DM, Hottes TS, Osei W, Adams E, Petric M, Sabaiduc S, Chan T, Mak A, Lem M, et al.: Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis 2010, 51:1017-1027.
• [44]Carcione DP, Giele C, Goggin LS, Kwan KS, Smith DW, Dowse GK, Mak DB, Effler P: Association between 2009 seasonal influenza vaccine and influenza-like illness during the 2009 pandemic: preliminary results of a large household transmission study in Western Australia. Euro Surveill 2010, 15(28):pii=19616. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19616 webcite
• [45]Iuliano AD, Reed C, Guh A, Desai M, Dee DL, Kutty P, Gould LH, Sotir M, Grant G, Lynch M, et al.: Notes from the field: outbreak of 2009 pandemic influenza a (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis 2009, 49:1811-1820.
• [46]Kelly HA, Grant KA, Fielding JE, Carville KS, Looker CO, Tran T, Jacoby P: Pandemic influenza H1N1 2009 infection in Victoria, Australia: no evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. Vaccine 2011, 29:6419-6426.
• [47]Pebody R, Andrews N, Waight P, Malkani R, McCartney C, Ellis J, Miller E: No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in England. Vaccine 2011, 29:2613-2618.
• [48]Echevarría-Zuno S, Mejía-Aranguré JM, Mar-Obeso AJ, Grajales-Muniz C, Robles-Pérez E, González-León M, Ortega-Alvarez MC, Gonzalez-Bonilla C, Rascón-Pacheco RA, Borja-Aburto VH: Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009, 374:2072-2079.
• [49]Garcia-Garcia L, Valdespino-Gomez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, Cruz-Hervert P, Cano-Arellano B, Garcia-Anaya A, Ferreira-Guerrero E, Baez-Saldana R, et al.: Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case–control study in Mexico City. BMJ 2009, 339:b3928.
• [50]Glezen WP: How did the 2008−2009 seasonal influenza vaccine affect the pandemic? Clin Infect Dis 2010, 51:1380-1382.
• [51]Kelly H, Barry S, Laurie K, Mercer G: Seasonal influenza vaccination and the risk of infection with pandemic influenza: a possible illustration of non-specific temporary immunity following infection. Euro Surveill 2010, 15(47):pii=19722. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19722 webcite
• [52]Mercer G, Kelly H: Seasonal influenza vaccination and the 2009 pandemic. Clin Infect Dis 2011, 52:828-829.
• [53]Buda S, Köpke K, Haas W: Epidemiologischer Steckbrief der pandemischen Influenza (H1N1) 2009 basierend auf Einzelfallmeldungen nach Infektionsschutzgesetz. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2010, 53:1223-1230.
• [54]Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, et al.: Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361:1935-1944.
• [55]Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, Belay B, Jain S, Cox C, Kamimoto L, et al.: Morbid Obesity as a Risk Factor for Hospitalization and Death Due to 2009 Pandemic Influenza A(H1N1) Disease. PLoS One 2010, 5:e9694.
• [56]Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, Matyas BT, the CP: A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis 2011, 52:1.
• [57]Murin S, Bilello KS: Respiratory Tract Infections: another reason not to smoke. Cleve Clin J Med 2005, 72:916-920.
• [58]Federal Statistical Office: Mikrozensus - Fragen zur Gesundheit - Rauchgewohnheiten der Bevölkerung 2009 [Microcensus - Health Questions - Smoking habits in the German population 2009]. the Federal Statistical Office, Mainz; 2009. http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Content/Publikationen/Fachveroeffentlichungen/Gesundheit/Gesundheitszustand/Rauchgewohnheiten5239004099004,property=file.pdf webcite
• [59]Brownstein JS, Mandl KD: Pediatric population size is associated with geographic patterns of Acute Respiratory Infections among adults. Ann Emerg Med 2008, 52:63-68.
• [60]Brownstein JS, Kleinman KP, Mandl KD: Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system. Am J Epidemiol 2005, 162:686-693.
• [61]Musher DM: How contagious are common respiratory tract infections? N Engl J Med 2003, 348:1256-1266.
• [62]Viboud C, Boelle P, Cauchemez S, Lavenu A, Valleron A, Antoine F, Carrat F: Risk factors of influenza transmission in households. Br J Gen Pract 2004, 54:684-689.